Results 71 to 80 of about 101,700 (245)

Pharmacokinetic Drug–Drug Interaction Potential of Oral Anticancer Drugs

Clinical Pharmacology &Therapeutics, EarlyView.
Drug–drug interaction (DDI) management is critical for safe and effective use of oral anticancer drugs (OADs). Our study objectives were to (i) compile clinically relevant pharmacokinetic (PK) DDI mechanisms for OADs and (ii) assess the prevalence of PK potential DDIs (PDDIs) in patients with advanced solid cancers.
Fatimah Alhurayri, Islam R. Younis, Shadia I. Jalal, Theodore F. Logan, Rohan Maniar, Steven M. Bray, Sara K. Quinney, Zeruesenay Desta, Todd C. Skaar, James E. Tisdale, Tyler Shugg   +10 more
wiley   +1 more source

Imatinib and hypophosphatemia: Case report and review of literature

Journal of Oncological Sciences, 2017
Imatinib mesylate is a potent inhibitor of the BCR-Abl kinases, c-Kit, PDGFR, and fms. Imatinib used for treatment of chronic myeloid leukemia and gastrointestinal stromal tumor. Imatinib has been well tolerated.
Erdem Şen, İrem Öner, Özlem Ata
doaj   +1 more source

Chronic myeloid leukemia patients sensitive and resistant to imatinib treatment show different metabolic responses. [PDF]

PLoS ONE, 2010
The BCR-ABL tyrosine kinase inhibitor imatinib is highly effective for chronic myeloid leukemia (CML). However, some patients gradually develop resistance to imatinib, resulting in therapeutic failure.
Jiye A, Sixuan Qian, Guangji Wang, Bei Yan, Sujiang Zhang, Qing Huang, Lingna Ni, Weibin Zha, Linsheng Liu, Bei Cao, Ming Hong, Hanxin Wu, Hua Lu, Jian Shi, Mengjie Li, Jianyong Li   +15 more
doaj   +1 more source

Pretreatment with VEGF(R)-inhibitors reduces interstitial fluid pressure, increases intraperitoneal chemotherapy drug penetration, and impedes tumor growth in a mouse colorectal carcinomatosis model [PDF]

, 2015
Cytoreductive surgery combined with intraperitoneal chemotherapy (IPC) is currently the standard treatment for selected patients with peritoneal carcinomatosis of colorectal cancer.
Ceelen, Wim, De Wever, Olivier, Descamps, Benedicte, Gremonprez, Félix, Izmer, Andrei, Vanhaecke, Frank, Vanhove, Christian   +6 more
core   +4 more sources

Cardiovascular toxicity induced by TKIs in patients with chronic myeloid leukaemia: Are women and men different?

ESC Heart Failure, Volume 12, Issue 2, Page 1447-1454, April 2025.
This study analyzes 148 patients (66 women and 82 men) with chronic myeloid leukemia treated with tyrosine kinase inhibitors, focusing on cardiovascular adverse events. The risk assessment, performed using the HFA/ICOS score, reveals sex‐specific differences: venous thrombosis is more common in women, while arterial thrombosis predominates in men.
Cristina Madaudo, Daniela Di Lisi, Antonio Cannatà, Federica Manfrè, Celeste Vullo, Marco Santoro, Ciro Botta, Salvatrice Mancuso, Sergio Siragusa, Alfredo Ruggero Galassi, Giuseppina Novo   +10 more
wiley   +1 more source

Urokinase Plasminogen Activator Receptor‐Associated Protein (uPARAP) as a Potential Next Generation Molecular Target for Treatment of Gastrointestinal Stromal Tumors (GIST)

International Journal of Cancer, EarlyView.
A key component of the collagen internalization and lysosomal degradation cellular machinery, uPARAP may contribute to cancer progression. Here, the authors explored the expression of uPARAP in gastrointestinal stromal tumors using well‐annotated clinical patient samples and specimens from cell line‐ and patient‐derived xenografts.
Chao‐Chi Wang, Flavia Paternostro, Agnieszka Wozniak, Lore De Cock, Luna De Sutter, Kimberly Verbeeck, Ulla Vanleeuw, Daniël Gorgels, Che‐Jui Lee, Raf Sciot, Patrick Schöffski   +10 more
wiley   +1 more source

Clinical Implication of Targeting of Cancer Stem Cells [PDF]

, 2012
The existence of cancer stem cells (CSCs) is receiving increasing interest particularly due to its potential ability to enter clinical routine. Rapid advances in the CSC field have provided evidence for the development of more reliable anticancer ...
Al-Hajj M, Bao S, Bardsley MR, Barlogie B, Bentzen SM, Bertout JA, Blazek ER, Bruns CJ, Brunsvig PF, C.J. Bruns, Cao X, Chen MS, Clayton S, Collins AT, Cortes J, Costello R, Dalerba P, Diehn M, Dou J, Dylla SJ, Eyler CE, Fischer S, Garvalov BK, Ghiaur G, Gibbs CP, Gilbert CA, H. Niess, Haferlach T, Hochhaus A, Hosen N, Huff CA, Hurwitz H, Jiang X, Jones RJ, Jones RJ, Jones RJ, Ju Z, K.-W. Jauch, Kanamori M, Kiladjian JJ, Klonisch T, Kojima T, Korpal M, L. Zhao, Li C, Liu G, Liu R, Liu S, Lonardo E, Mauro MJ, McDermott SP, Merante S, Mimeault M, Moserle L, O’Brien SG, Park CY, Phillips TM, Platet N, Q. Bao, Rasheed ZA, Reya T, Reya T, Richardson GD, Roeder I, Seidel S, Singh A, Singh SK, Strojnik T, Stupp R, Suh MR, Szotek PP, Tang C, Tang M, Todaro M, Tu LC, Vermeulen L, Wilson BJ, Wright MH, Xu N, Y. Zhao, Yu F, Zhao C, Zhou BB   +82 more
core   +1 more source

Integrating Single‐Cell and Spatial Transcriptomes in HGSOC to Decipher the Metastasis‐Associated Biomarkers

iNew Medicine, EarlyView.
ABSTRACT High‐grade serous ovarian cancer (HGSOC) is the most common and lethal histological subtype of ovarian cancer. This study aimed to identify peritoneal metastasis‐associated biomarkers of HGSOC to provide directions for subsequent treatment. Transcriptome data were extracted from the GEO database and literature. Differential expression analysis,
Jing Zhu, Zhicheng Yu, Yang Zhang, Hui Hong, Xiaoli Wang, Shan Jiang, Ying Zhou, Cheng Peng, Hongbo Chen   +8 more
wiley   +1 more source

New Hydrazone Derivatives Featuring Isatin and Piperazine Moieties: Synthesis, Cytotoxicity Evaluation, and Molecular Modeling Studies

Journal of Applied Toxicology, EarlyView.
ABSTRACT In this study, ten novel compounds (IPH1–IPH10) were designed by integrating three pharmacophores (isatin, piperazine, and hydrazone) commonly found in the molecular structures of anticancer agents. The target molecules were obtained by the reaction of in‐house prepared 4‐(4‐(pyridin/pyrimidin‐2‐yl)piperazin‐1‐yl)benzohydrazide with various ...
Semiha Köprü, Münevver Baran, Miyase Gözde Gündüz, Şengül Dilem Doğan   +3 more
wiley   +1 more source

Rapidly progressive dyspnea in gastrointestinal stromal tumor (GIST) with imatinib cardiac toxicity

Journal of Community Hospital Internal Medicine Perspectives, 2018
Gastrointestinal stromal tumors (GISTs) are rare and current estimates range from 4,000 to 6,000 number of GIST cases in the USA annually. Imatinib, a tyrosine kinase inhibitor, has shown a survival benefit in GISTs, and the presence of KIT mutation ...
Adnan Asif Parvez Ghias, Shahzeem Bhayani, David J. Gemmel, Sudershan K. Garg   +3 more
doaj   +1 more source